First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Concerns over the competitive landscape and potential regulatory hurdles are weighing on investor sentiment, overshadowing initial optimism around ALRN-6924.
★ Analysts see FY2027 revenue reaching $128M — +83.0% growth in a single year.
What Could Go Wrong
1Increased competition in the oncology space could pressure Aileron's market position, particularly from larger firms with similar p53-targeting therapies.
2Regulatory delays in clinical trial approvals could extend the timeline for ALRN-6924's market entry.
3Regulatory changes that could impact drug approval processes
4Technological disruption in drug delivery systems
5Emergence of alternative therapies targeting p53 pathways
6Increased competition from larger biotech firms with more resources
7High cash burn rate with negative free cash flow of -42.4%
8Dependence on external funding to sustain operations